HeartBeam to prioritize heart attack detection, shares strategic focus

HeartBeam, Inc. has decided to prioritize heart attack (myocardial infarction) detection, redirecting the majority of its resources toward this opportunity. The company will continue limited commercialization of its existing arrhythmia product but will not build a large commercial organization around it. HeartBeam also plans to advance its 12-lead patch toward FDA clearance and seek a strategic partner for its commercialization.